BrisSynBio start-up wins Unit DX lab space at Bio-Start Awards 2017 – University of Bristol
|
BrisSynBio start-up wins Unit DX lab space at Bio-Start Awards 2017
University of Bristol Zentraxa is the first start-up from the University of Bristol’s Synthetic Biology Research Centre, BrisSynBio, part of the Bristol BioDesign Institute. Focusing on the biomolecular design and engineering aspects of synthetic biology, it has been … |
University of Bristol |
BrisSynBio start-up wins Unit DX lab space at Bio-Start Awards 2017
University of Bristol Zentraxa is the first start-up from the University of Bristol’s Synthetic Biology Research Centre, BrisSynBio, part of the Bristol BioDesign Institute. Focusing on the biomolecular design and engineering aspects of synthetic biology, it has been … |
|
Searching in the immune checkpoint black box
Nature.com Similarly, loss of Ptpn2 also sensitized tumours to immunotherapy in vivo. Ptpn2-null B16 tumours were significantly more sensitive to PD1 inhibition — but did not show any growth disadvantage in the absence of T cell-mediated immunity or PD1 inhibition. |
Technology Networks |
Ageing is Exacerbated by Alterations of Stem Cell Circadian Rhythm
Technology Networks It is widely believed that, with the passage of time, stem cells cease to differentiate between day and night cycles, in other words they lose their circadian rhythm, and that this loss promotes ageing. However, this has been found not to be the case … Low-calorie diet may slow aging by ‘rejuvenating biological clock’Medical News Today Aging is exacerbated by alterations of stem cell circadian rhythm(e) Science News (press release) (registration) |
PharmaTimes |
£2m UK consortium to tackle gene therapy
PharmaTimes A new consortium, led by Oxford BioMedica, will embark on a two-year, £2 million project focused on gene and cell therapy manufacturing. Other partners include the Cell and Gene Therapy Catapult, Stratophase and Synthace, and the collaboration is … Oxford BioMedica to lead £2m gene therapy collaboration projectStock Market Wire |
PharmaTimes |
£2m UK consortium to tackle gene therapy
PharmaTimes A new consortium, led by Oxford BioMedica, will embark on a two-year, £2 million project focused on gene and cell therapy manufacturing. Other partners include the Cell and Gene Therapy Catapult, Stratophase and Synthace, and the collaboration is … |